SLC6A3 and clear cell renal carcinoma: Sertraline induced dose‐dependent cytotoxicity in Caki‐1 and A498 cells, significantly reducing proliferation at 25–50 μMSLC6A3 identified as a potential biomarker for clear cell renal cell carcinomas, with upregulated mRNA but lower protein levels, suggesting post‐transcriptional regulationHigh SLC6A3 expression correlated with shorter recurrence‐free survival, indicating prognostic valueSertraline, an SLC6A3 inhibitor, showed anticancer potential, supporting further investigation into its therapeutic efficacy and mechanisms